Creon
These highlights do not include all the information needed to use CREON safely and effectively. See full prescribing information for CREON. CREON (pancrelipase) delayed-release capsules for oral use Initial U.S. Approval: 2009
Approved
Approval ID
45b9a46b-3294-4604-8aea-60624d663020
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Jan 27, 2012
Manufacturers
FDA
Atlantic Biologicals Corps
DUNS: 047437707
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Pancrelipase
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code17856-1212
Application NumberNDA020725
Product Classification
M
Marketing Category
C73594
G
Generic Name
Pancrelipase
Product Specifications
Route of AdministrationORAL
Effective DateJanuary 27, 2012
FDA Product Classification
INGREDIENTS (8)
PANCRELIPASE LIPASEActive
Quantity: 12000 [USP'U] in 1 1
Code: 8MYC33932O
Classification: ACTIB
cetyl alcoholInactive
Code: 936JST6JCN
Classification: IACT
PANCRELIPASE AMYLASEActive
Quantity: 60000 [USP'U] in 1 1
Code: YOJ58O116E
Classification: ACTIB
hypromellosesInactive
Code: 3NXW29V3WO
Classification: IACT
PANCRELIPASE PROTEASEActive
Quantity: 38000 [USP'U] in 1 1
Code: 3560D81V50
Classification: ACTIB
dimethiconeInactive
Code: 92RU3N3Y1O
Classification: IACT
POLYETHYLENE GLYCOLSInactive
Code: 3WJQ0SDW1A
Classification: IACT
triethyl citrateInactive
Code: 8Z96QXD6UM
Classification: IACT